Photo from João Alessi/Twitter
Jul 19, 2023, 18:03
Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – João Alessi
Glad to share our paper recently published in Nature. In which, we report the impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC. Collaboration b/w Dana-Farber and Memorial Sloan Kettering Radiation Oncology.
For article: Click here
Source: João Alessi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38